Clinical trial · Interventional
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Collection of Biological Resources During Medical Care of Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase for an Epigenetic Study of Leukemic Stem Cells
NCT03481868CI-TRIAL-00075850EPIKunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia (CML) | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.85 |
| Chronic Phase | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of blood and bone marrow | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chronic Myeloid Leukemia
- description
- Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
- interventionNames
- Biological: Collection of blood and bone marrow
Primary outcomes (1)
- measure
- Epigenetic dysregulations of in vivo TKI-resisting CML cells
- timeFrame
- at Day 0 and Month3
- description
- Epigenetic and/or gene expression anomalies in in vivo TKI-selected CML cells for 3 months in comparison with anomalies identified at D0
Secondary outcomes (3)
- measure
- relationship between epigenetic/gene expression profile and CML burden (M3)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient newly diagnosed for Chronic Myeloid Leukemia in chronic phase * Patient older than 18 years old * Patient who received no treatment for CML at the time of sampling on D0 * Intention of prescription with first-line treatment with TKI only * Choice of first-line CML treatment by TKI only * Patient having signed an informed consent * Patient with a social security system Exclusion Criteria: * Contra-indication to the use of TKI * Probability of poor compliance during treatment * Patients already treated for CML
References
Publications (0)
Data not yet available
No reference posted for this study.